Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | ||
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
Agenda
Item | Who | Talking Points |
---|---|---|
DGAB Updates |
| |
BPSC Updates |
| |
September Steering Committee Updates |
| |
ICDC Site Updates |
| |
ICDC Next Phase Planning |
|
Minutes (Not Verbatim)
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Previous Meeting Minutes (Not Verbatim)
TH- Possible COI with people working on the RFI and then responding to the RFI. Dr. Doroshow signed off on RFI. Unless there are issues noted the RFI should be published in ~ 2 weeks. Many ideas came from initial focus groups.
JO- What type of plans can be put in place to advertise the RFI? Can we leverage NCI social media?
TH- We can send to anyone we want, including Cancer Center Directors, they have collaborations with vet clinic schools, some of the foundations.
AL- Circulate to PRECINCT as well.
TH- Deadline for response is Dec. 1st.
AL- Giving presentation to the children's oncology group. Touched base with CIN and PRECINCT. The talk is osteo-focused.
Action items